Skip to content
Linkedin page opens in new window
Linkedin page opens in new window
Therawis
therapies wisely applied
Home
About
Therawis Pharma
Management
Clinical Services
Therawis Diagnostics
Management
Diagnostics
Pipeline
therascreen PITX2
ExosomeDx
Platin-R
Publications
Press Releases
Investigator Login
Partners
Contact
Search:
Home
About
Therawis Pharma
Management
Clinical Services
Therawis Diagnostics
Management
Diagnostics
Pipeline
therascreen PITX2
ExosomeDx
Platin-R
Publications
Press Releases
Investigator Login
Partners
Contact
Press Releases
You are here:
Home
Press Releases
Therawis Diagnostics' licensing and development partner QIAGEN launches predictive therascreen PITX2 test in Europe to guide treatment in high-risk breast cancer.
February 7, 2018
Therawis Diagnostics and QIAGEN enter into a development and commercialization agreement on predictive biomarkers in oncology.
May 26, 2016
Go to Top